Dr. Leonard on Precision Medicine in Hematologic Malignancies

John P. Leonard, MD
Published: Thursday, Aug 24, 2017



John P. Leonard, MD, associate dean of Clinical Research, interim chair of the Department of Medicine, Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the advance of precision medicine across hematologic malignancies.

Like much in oncology, the theme that is coming through in hematologic malignancies is precision medicine and precision science, Leonard explains. Researchers are focused on setting disease subcategories, whether that is for targeted therapies and identifying molecular targets within subsets of patients, or for identifying minimal residual diseas. This is so that physicians can determine who needs more or less therapy, a different therapy, or can identify when relapse is occurring.

Those are the major areas across hematologic malignancies, and that is the theme in cancer care in general, he concludes.


John P. Leonard, MD, associate dean of Clinical Research, interim chair of the Department of Medicine, Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the advance of precision medicine across hematologic malignancies.

Like much in oncology, the theme that is coming through in hematologic malignancies is precision medicine and precision science, Leonard explains. Researchers are focused on setting disease subcategories, whether that is for targeted therapies and identifying molecular targets within subsets of patients, or for identifying minimal residual diseas. This is so that physicians can determine who needs more or less therapy, a different therapy, or can identify when relapse is occurring.

Those are the major areas across hematologic malignancies, and that is the theme in cancer care in general, he concludes.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesJan 30, 20182.0
Cancer Summaries and Commentaries™: Update from San Diego - Advances in the Treatment of Multiple MyelomaJan 31, 20181.5
Publication Bottom Border
Border Publication
x